Last updated: September 18, 2026
Insulin glulisine, marketed primarily as Apidra by Sanofi, is a mature rapid-acting insulin analog with limited remaining patent protection, declining strategic importance within Sanofi’s diabetes portfolio, and intensifying competition from insulin aspart, insulin lispro, ultra-rapid formulations, biosimilars, and lower-cost human insulin. Sanofi does not separately disclose current Apidra revenue, preventing a precise product-level valuation. Public filings indicate that Apidra is a smaller contributor than Sanofi’s basal-insulin brands, particularly Lantus and Toujeo.
What is insulin glulisine and how is Apidra positioned?
Insulin glulisine is a recombinant rapid-acting human insulin analog. It differs from human insulin through substitutions at positions B3 and B29 that reduce self-association and allow faster absorption after subcutaneous administration. Apidra is approved for glycemic control in adults and pediatric patients with diabetes mellitus. It is administered by subcutaneous injection before meals and can also be used in continuous subcutaneous insulin infusion systems under product-label conditions (U.S. Food and Drug Administration [FDA], 2004).
Apidra is available in:
| Product form |
Typical strength |
Delivery format |
| Apidra vial |
U-100 |
10 mL vial |
| Apidra SoloStar |
U-100 |
Prefilled disposable pen |
| Apidra cartridges or pen systems |
Market-dependent |
Availability varies by jurisdiction |
The principal commercial value proposition is meal-time glucose control with a rapid onset relative to regular human insulin. That positioning is no longer differentiated enough to command strong pricing against NovoLog, Humalog, Fiasp, Lyumjev, biosimilar products, and low-cost human insulin.
When did insulin glulisine receive FDA approval?
The FDA approved Apidra in April 2004 under New Drug Application 021629. The product was developed by Aventis, which later became part of Sanofi (FDA, 2004).
Key FDA milestones
| Event |
Date |
| FDA approval of Apidra |
April 2004 |
| Initial approved use |
Adults with diabetes |
| Pediatric labeling expansion |
Subsequently expanded; current labeling includes pediatric use |
| Primary regulatory category |
Insulin analog biologic marketed under an NDA |
| Current U.S. status |
Approved and marketed, subject to commercial availability |
The regulatory framework for insulin products changed in the United States in March 2020, when insulin products were transitioned from the Federal Food, Drug, and Cosmetic Act to the Public Health Service Act. Insulin glulisine is therefore treated as a biologic product for U.S. regulatory purposes, although Apidra was originally approved as a drug under an NDA (FDA, 2020).
What patents protect insulin glulisine and Apidra?
The original U.S. patent estate for insulin glulisine is mature and no longer provides meaningful exclusivity against ordinary follow-on competition.
A key patent associated with insulin glulisine is U.S. Patent No. 5,922,675, covering insulin analog compositions and related subject matter. The patent issued in 1999 and had a term extending into the early 2010s, subject to applicable patent-term adjustments and extensions. The core composition protection has expired.
| IP category |
Current commercial relevance |
| Insulin glulisine composition patents |
Core terms expired |
| Apidra formulation patents |
Limited remaining exclusionary value or expired, depending on jurisdiction |
| Pen-device patents |
May belong to device suppliers and may not block all insulin-glulisine products |
| Manufacturing patents |
Could remain relevant for particular processes, but do not recreate composition exclusivity |
| Method-of-use patents |
Limited ability to prevent substitution in a crowded rapid-acting insulin market |
The commercial barrier is therefore no longer the molecule itself. The more relevant barriers are manufacturing scale, regulatory comparability, device integration, reimbursement access, physician familiarity, and supply reliability.
When does Apidra lose exclusivity?
Apidra’s principal regulatory exclusivity periods expired years ago. The product has no current new-molecular-entity exclusivity that would block development of competing insulin glulisine products.
The exact U.S. launch date for a follow-on insulin glulisine product depends on FDA review, reference-product protections, patent certifications, and litigation. Because Apidra’s core patents are mature, a Paragraph IV challenge would face a different risk profile from a challenge against a recently launched biologic.
Exclusivity timeline
| Exclusivity type |
Approximate status |
| Five-year new chemical entity exclusivity |
Expired years ago |
| Three-year clinical-investigation exclusivity |
Expired |
| Core composition patent protection |
Expired |
| Orange Book patent-based delay risk |
Low relative to newly protected products |
| Biologic reference-product exclusivity |
Expired or no longer commercially determinative |
| Current market protection |
Brand recognition, supply, formulary access, and device economics |
Insulin glulisine is not commercially protected by a durable patent moat. A competitor can seek approval through an abbreviated pathway or a biologic follow-on pathway, depending on the product’s regulatory classification and development strategy.
What is the Orange Book status of Apidra?
Apidra was historically listed in the FDA Orange Book because it was approved as an NDA product. The U.S. insulin transition to biologic regulation changed the regulatory context, but the relevant practical point is that the product’s principal patent protection is not current.
The Orange Book remains relevant for historical patents, dosage forms, and approval records. It is less important for assessing present-day Apidra pricing power than formulary contracts and pharmacy-benefit-manager treatment.
A competitor seeking approval before the 2020 regulatory transition could have relied on an abbreviated new drug application framework. For products developed after the transition, the applicable pathway is generally the biosimilar or interchangeable-biologic framework under section 351(k) of the Public Health Service Act, although the exact pathway depends on the reference product and product-specific FDA requirements (FDA, 2020).
Are there Paragraph IV challenges to Apidra?
No major publicly visible, market-defining Paragraph IV litigation campaign against Apidra has established a durable barrier to follow-on insulin glulisine entry.
That result reflects the product’s age and the limited economic value of pursuing prolonged patent litigation against a mature rapid-acting insulin. A challenger would typically focus on:
- expired composition patents;
- any remaining formulation or device claims;
- noninfringement or invalidity positions;
- FDA pathway selection;
- interchangeability and substitution economics;
- payer contracts rather than patent litigation alone.
The absence of high-profile litigation does not mean that no patent disputes are possible. It indicates that Apidra’s competitive exposure is driven more by commercial execution than by unresolved molecule-level patent rights.
What formulations and delivery systems are protected by Apidra patents?
Apidra’s product-level protection historically covered insulin-glulisine formulations, dosage forms, and delivery presentations. The commercial forms include vials and disposable pen devices.
Formulation and device risks
The active ingredient is not the only relevant IP layer. A competitor may need to address:
- insulin-glulisine stability and excipient composition;
- concentration and container-closure systems;
- cartridge compatibility;
- pen-injector mechanics;
- manufacturing and purification processes;
- labeling and administration instructions.
Device patents can create a practical obstacle even after active-ingredient patents expire. They do not necessarily prevent a competing insulin glulisine product if the competitor uses a distinct pen design, vial presentation, or delivery system.
Apidra’s pen presentation also faces competition from Novo Nordisk’s FlexPen and FlexTouch systems, Eli Lilly’s KwikPen, and connected insulin-delivery systems. Device convenience has become a commercial differentiator, but Apidra does not have a clear platform advantage.
How does insulin glulisine compare with insulin aspart and insulin lispro?
Insulin glulisine competes in the same rapid-acting insulin segment as insulin aspart and insulin lispro. Clinical differentiation is limited for most patients when products are used correctly and titrated appropriately.
| Attribute |
Insulin glulisine |
Insulin aspart |
Insulin lispro |
| Main brand |
Apidra |
NovoLog, Fiasp |
Humalog, Lyumjev |
| Developer |
Sanofi |
Novo Nordisk |
Eli Lilly |
| Product class |
Rapid-acting insulin analog |
Rapid-acting or ultra-rapid analog |
Rapid-acting or ultra-rapid analog |
| Core use |
Mealtime glucose control |
Mealtime glucose control |
Mealtime glucose control |
| Competitive strength |
Established clinical familiarity |
Broad formulary and device presence |
Broad formulary and biosimilar ecosystem |
| Ultra-rapid versions |
No major Apidra equivalent |
Fiasp |
Lyumjev |
| Pricing pressure |
High |
High |
High |
Novo Nordisk and Eli Lilly have stronger commercial scale in prandial insulin. Their portfolios include both conventional rapid-acting products and newer ultra-rapid formulations. This gives them more opportunities to negotiate formulary placement across patient segments.
Apidra is also disadvantaged by Sanofi’s commercial concentration on basal insulin, especially Lantus and Toujeo. Rapid-acting insulin is often selected as part of a broader diabetes regimen, and manufacturers with stronger basal-bolus portfolios can negotiate more effectively with payers.
What is the financial trajectory of Apidra?
Sanofi does not generally report Apidra revenue as a separate line item in recent annual reports. The company reports diabetes sales through broader product and franchise categories, with Lantus and Toujeo receiving greater investor attention. As a result, a reliable current Apidra revenue series cannot be constructed from public filings.
Financial trajectory
| Period |
Market position |
Financial implication |
| 2004 to early 2010s |
Newer rapid-acting analog with brand protection |
Higher pricing and stronger differentiation |
| Mid-2010s |
Mature product facing NovoLog and Humalog competition |
Declining pricing power |
| Late 2010s |
Intensifying U.S. insulin affordability scrutiny |
Greater rebate and net-price pressure |
| 2020 onward |
Biologic transition and follow-on competition |
Lower legal barriers to competition |
| Current market |
Mature, low-growth rapid-acting insulin |
Limited standalone strategic value |
Sanofi’s insulin franchise has experienced structural pressure from lower net prices, payer rebates, biosimilar and follow-on insulin competition, and lower-cost channels. Lantus remains commercially important, but Apidra is not identified as a major growth driver in Sanofi’s public strategy or financial reporting (Sanofi, 2024).
Revenue exposure is therefore more relevant at the portfolio level than at the Apidra level. The main financial risks are:
- contracting pressure from pharmacy benefit managers;
- Medicare and commercial formulary restrictions;
- lower-cost insulin programs;
- substitution into insulin lispro or insulin aspart;
- loss of prescriptions to ultra-rapid products;
- declining physician attention to a mature product;
- manufacturing and supply-chain costs.
Which companies are challenging Apidra commercially?
The principal competitive companies are Novo Nordisk and Eli Lilly. Biocon Biologics, Viatris, Wockhardt, and other insulin manufacturers can also affect pricing through follow-on and biosimilar products, although the competitive impact varies by country and regulatory pathway.
Competitive landscape
| Company |
Relevant products or capabilities |
Competitive impact |
| Novo Nordisk |
NovoLog and Fiasp |
Strong branded rapid-acting franchise and device integration |
| Eli Lilly |
Humalog and Lyumjev |
Broad rapid-acting portfolio and biosimilar experience |
| Biocon Biologics |
Insulin biosimilar capabilities |
Potential lower-cost competition |
| Viatris |
Biosimilar commercialization infrastructure |
Payer and channel pressure |
| Wockhardt and regional manufacturers |
Insulin manufacturing |
Geographic and price competition |
| Sanofi |
Apidra, Lantus, Toujeo |
Incumbent supply and portfolio access |
The strongest competitive threat is not a single Apidra-specific generic launch. It is substitution across the entire rapid-acting insulin class.
What is the biosimilar risk for insulin glulisine?
Biosimilar risk is moderate to high. Insulin products are biologics, but their manufacturing platforms are established, analytical tools are advanced, and clinical use is widespread. These factors reduce the scientific uncertainty associated with follow-on development.
The key commercial distinction is between approval and automatic substitution. FDA approval of a biosimilar does not automatically establish interchangeability. An interchangeable designation can improve pharmacy substitution prospects, but payer contracts and state substitution laws remain important.
Biosimilar entry scenarios
| Scenario |
Likely market effect |
| One follow-on insulin glulisine entrant |
Moderate price pressure |
| Multiple interchangeable entrants |
Material net-price erosion |
| Follow-on product with a differentiated pen |
Greater pharmacy and patient adoption |
| Payer-preferred entrant |
Rapid share loss for Apidra |
| Low-cost human insulin expansion |
Downward pressure in price-sensitive segments |
Apidra’s competitive exposure is higher in tender-driven and public-payer markets than in channels where physician familiarity or device preference supports brand retention.
What patent litigation affects insulin glulisine?
No major current patent dispute appears to create a significant near-term barrier to Apidra competition. The litigation risk is more likely to arise around manufacturing processes, delivery devices, interchangeability, or market-entry timing than around the core insulin-glulisine molecule.
For investors and licensing teams, the important legal questions are:
- whether any unexpired country-specific patents cover a commercial presentation;
- whether a follow-on product uses a protected device;
- whether an applicant receives an FDA complete response letter;
- whether Sanofi asserts process or formulation patents;
- whether parties settle entry timing;
- whether a product receives an interchangeable designation.
How strong is the insulin glulisine patent estate?
The patent estate is weak as a current exclusivity asset and moderate as a historical defensive asset.
| Factor |
Assessment |
| Core molecule protection |
Weak; expired |
| Remaining formulation protection |
Limited and jurisdiction-specific |
| Device protection |
Potentially relevant but design-around possible |
| Manufacturing know-how |
Potentially valuable, not equivalent to market exclusivity |
| Regulatory exclusivity |
Expired |
| Litigation leverage |
Low to moderate |
| Commercial durability |
Dependent on contracts and supply |
Sanofi’s strongest protection is likely operational rather than legal. Scale, manufacturing consistency, product quality, distribution, payer relationships, and physician familiarity can delay substitution but cannot prevent lower-cost competition indefinitely.
What are the generic and follow-on launch risks?
The most likely launch pattern is gradual share erosion rather than an abrupt Apidra collapse. Rapid-acting insulin markets are heavily influenced by rebates, formularies, and supply contracts. A follow-on entrant with limited manufacturing capacity may have little effect. A product backed by a major payer contract can change market share quickly.
Launch-risk assessment
| Risk |
Probability |
Commercial effect |
| Low-cost follow-on insulin glulisine |
Medium |
Moderate price erosion |
| Interchangeable follow-on product |
Medium |
High substitution risk |
| New ultra-rapid product displacing Apidra |
High |
Gradual share erosion |
| Formulary exclusion |
Medium to high |
Significant volume loss |
| Manufacturing interruption |
Low to medium |
Immediate supply and reputation risk |
| Patent-based launch delay |
Low |
Limited current relevance |
How does Apidra compare with competing rapid-acting insulins financially?
Apidra has lower strategic visibility than NovoLog and Humalog because Sanofi’s diabetes growth narrative is centered more heavily on basal insulin and newer metabolic products. Novo Nordisk and Eli Lilly also have broader diabetes ecosystems, including obesity and metabolic disease franchises that support payer relationships and physician reach.
Apidra’s economics depend on net price rather than list price. Gross sales can overstate actual profitability because insulin rebates and discounts are substantial. A mature insulin analog can retain revenue while losing margin if manufacturers defend volume through higher rebates.
The product’s likely financial trajectory is:
- stable-to-declining prescription volume;
- continued net-price pressure;
- reduced marketing priority;
- rising dependence on formulary access;
- limited upside without a new delivery system or label expansion.
What licensing deals affect insulin glulisine?
No major recent licensing transaction has repositioned Apidra as a growth asset. Sanofi has historically relied on internal commercialization and established manufacturing relationships for its insulin portfolio. The more relevant transaction opportunities involve:
- regional commercialization rights;
- contract manufacturing;
- follow-on insulin partnerships;
- pen-device supply agreements;
- co-development of connected delivery systems.
A licensing transaction for Apidra would likely be motivated by geographic reach, manufacturing utilization, or portfolio rationalization rather than by patent monetization.
What is the outlook for insulin glulisine through 2030?
Apidra is likely to remain commercially available in major markets, but its market share and net pricing are expected to face continued pressure. The product can retain a role where physicians, patients, or payers prefer its established use or where supply conditions favor Sanofi. It is unlikely to become a major growth product without meaningful formulation, device, or access innovation.
The key variables are:
- adoption of biosimilar or interchangeable insulin;
- payer management of rapid-acting insulin;
- growth of connected pens and automated insulin delivery;
- expansion of ultra-rapid insulin use;
- regional price controls;
- Sanofi’s portfolio allocation;
- manufacturing reliability.
Key Takeaways
- Insulin glulisine is a mature rapid-acting insulin analog marketed primarily as Apidra.
- FDA approval occurred in 2004, and core regulatory and patent exclusivity has expired.
- The current patent estate offers limited protection against follow-on competition.
- Sanofi does not separately disclose current Apidra revenue, so product-level financial modeling requires estimates rather than reported figures.
- The largest competitive threats are NovoLog, Fiasp, Humalog, Lyumjev, biosimilar insulin, and lower-cost human insulin.
- Apidra’s financial trajectory is likely flat to declining, with greater net-price pressure and lower strategic priority.
- Formulary access, rebates, manufacturing scale, and device compatibility are more important than molecule-level patent protection.
- Biosimilar and interchangeable insulin products present the most significant long-term erosion risk.
FAQs
Is insulin glulisine interchangeable with insulin lispro?
No. Both are rapid-acting insulin analogs, but they are different biological products. Substitution depends on clinical judgment, product labeling, payer rules, and applicable pharmacy-substitution law.
Does Apidra have orphan-drug exclusivity?
No. Apidra is not an orphan product, and orphan-drug exclusivity is not a relevant protection for insulin glulisine.
Can a generic company launch insulin glulisine without a patent license?
Potentially yes, if the relevant patents have expired or the applicant uses a noninfringing product and obtains regulatory approval. The pathway depends on the product’s classification and the jurisdiction.
Is Apidra approved for use in insulin pumps?
Apidra labeling permits use in continuous subcutaneous insulin infusion systems subject to the product label and device-specific requirements. Pump compatibility and stability requirements must be evaluated separately.
What is the main investment risk for Apidra?
The main risk is commercial erosion from payer contracting, follow-on insulin, and substitution into competing rapid-acting or ultra-rapid products, rather than a newly emerging patent challenge.
References
- U.S. Food and Drug Administration. (2004). Apidra insulin glulisine injection, prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2020). Implementation of the Biologics Price Competition and Innovation Act transition provisions. https://www.fda.gov
- U.S. Patent and Trademark Office. (1999). U.S. Patent No. 5,922,675. https://patents.google.com/patent/US5922675
- Sanofi. (2024). Universal registration document and annual financial report 2023. https://www.sanofi.com
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
